Related Experiment Video

Updated: May 24, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Long-term independent predictors of positive response to cardiac resynchronization therapy

Mauro Toniolo1, Gabriele Zanotto, Andrea Rossi

  • 1Division of Cardiology, Department of Biomedical and Surgical Sciences, University of Verona, Verona, Italy.

Journal of Cardiovascular Medicine (Hagerstown, Md.)
|March 8, 2012
PubMed

Insights

Cardiac resynchronization therapy (CRT) improves outcomes for heart failure patients. Nonischemic cause, left bundle-branch block, and lower baseline LVESV/BSA predict positive CRT response and better long-term prognosis.

Area of Science:

  • Cardiology
  • Heart Failure Management
  • Medical Devices

Background:

  • Cardiac resynchronization therapy (CRT) is a key treatment for refractory heart failure.
  • Long-term predictors of CRT response and patient outcomes require further investigation.

Purpose of the Study:

  • To identify baseline characteristics predicting positive response to CRT.
  • To evaluate the impact of these predictors on long-term mortality, morbidity, and ventricular function recovery.

Main Methods:

  • Retrospective follow-up study of 211 heart failure patients receiving CRT.
  • Analysis of baseline clinical characteristics including cause of heart failure, bundle-branch block type, and LVESV/BSA.
  • Evaluation of long-term prognosis, survival, and rehospitalization rates.

Main Results:

  • Nonischemic heart failure etiology, left bundle-branch block, and LVESV/BSA ≤ 106 ml/m² were independent predictors of CRT response.
  • Reduced LVESV/BSA post-CRT correlated with improved survival and decreased heart failure rehospitalization.

Conclusions:

  • Patient selection for CRT can be improved by considering heart failure cause, bundle-branch block type, and baseline LVESV/BSA.
  • Optimizing patient selection enhances the likelihood of benefiting from CRT.
Abstract

More Related Videos

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.